Inherited, congenital and acquired disorders by hemostasis (vascular, platelet & plasmatic phases) with repercussions by Arrieta Blanco, Juan José et al.
Med Oral Patol Oral Cir Bucal. 2014 May 1;19 (3):e280-8.                                                                                    Hemostasis disorders with repercussions in the odontostomatological treatments
             
e280
Journal section: Medically compromised patients in Dentistry
Publication Types: Review
Inherited, congenital and acquired disorders by hemostasis (vascular, platelet 
& plasmatic phases) with repercussions in the therapeutic oral sphere
Juan-José Arrieta-Blanco 1, Ricardo Oñate-Sánchez 2, Federico Martínez-López 3, Daniel Oñate-Cabrerizo 4, 
Maria-del Carmen Cabrerizo-Merino 5
1 Medical Doctor. Stomatologist. Associate Chief of Odontostomatological Service of the Jiménez Díaz-Capio Foundation. 
Madrid. Autonomic University of Madrid
2 Medical Doctor. Stomatologist. Permanent Professor of University. Docent Unit of Special Patients. University Odontological 
Clinic. Faculty of Medicine. Murcia
3 Medical Doctor. Odontologist. USBD Medical Center of Fuente Álamo and Mazarrón. Contributor of Docent Unit of Special 
Patients. University Odontological Clinic. Faculty of Medicine. Murcia
4 Doctor. Contributor of Docent Unit of Special Patients. University Odontological Clinic. Faculty of Medicine. Murcia
5 Medical Doctor. Stomatologist. USBD Medical Center of Ranero. Associate professor of Docent Unit of Special Patients. 
University Odontological Clinic. Faculty of Medicine. Murcia
Correspondence:
Unidad Docente de Pacientes Especiales
Clínica Odontológica Universitaria 2ª Planta  
Hospital Morales Meseguer
Avenida  Marqués de los Velez  s/n 
30.008 Murcia, Spain 
reosan@um.es
Received: 18/09/2013
Accepted: 29/09/2013
Abstract
The hemostasis alterations, either congenital or hereditary origin, and acquired, are circumstances that hinder oral 
care to patients who suffer them and also generates in the professional who has to attend, high stress. Bleeding 
control once established and dental treatment planning, both in the aspect of preparation, as the realization of 
the odonto-stomatological therapeutic, has suffered updates that do need to remember certain aspects of the care 
of these patients. But we must not forget that the hematologist or internist who controls the patient’s medical 
condition, is a cornerstone for the planning and implementation of treatment plans. We must also remember that, 
in certain circumstances, treatment should be performed in a hospital setting. In this review, we aim to provide 
the odonto-stomatologist guidance on how to address the problem and provide simple and updated guidelines to 
apply in the treatment of these people.
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Introduction
Hemostasis means the whole body’s physiological 
processes whose ultimate goal is to prevent blood 
loss when altering the integrity of the vascular system 
structures. When this delicate balance is disturbed, can 
appear both clinical bleeding (haemorrhagic diathesis) 
and hypercoagulable (thromboembolic syndromes).
Much of the odontostomalogical activity may result oral 
bleeding without danger to the patient, but sometimes 
this represents a serious risk when the ability to control 
bleeding is diminished by alteration in some phase of 
hemostasis, either congenitally or acquired. These 
patients may have bleeding gums, characterized by 
being more persistent than more intense, so the volume 
of blood loss could be significant. This fact is important 
because mild or minimal trauma, such as those ones 
that may happen eating or brushing your teeth, may be 
sufficient to cause gingival bleeding in these patients (1). 
It is therefore essential that the stomatologist properly 
recognize and identify patients at risk of bleeding during 
dental treatment to prevent or decide what measures to 
take for bleeding.
In the hemostasis process are different stages and 
phases, which involved different cell lines and different 
proteins (soluble in idle status) of blood. The final 
result is the formation of a red/fibrin mesh (insoluble 
protein in the blood) inside it encompassed blood cells 
(platelets, erythrocytes) are found. This grid/mesh acts 
as a barrier and prevents the loss of blood vessel injury 
by until the vascular tree is repaired. Before vascular 
injury in hemostasis, will produce two successive 
stages, with primary and secondary hemostasis three 
phases: a) vascular phase b) platelet phase c) plasma 
phase with plasma proteins involved in coagulation and 
clot removal later by fibrinolysis.
I Revision
I) Primary Hemostasis
It’s the primary hemostatic plug formation. Depends on 
the vascular integrity (endothelium and subendothelium), 
and platelet function (quantitative and qualitative). 
During this stage two mechanisms are involved: one 
vessel and another platelet.
A) Vascular spasm.: This vasoconstrictor response 
serves two purposes: it reduces blood loss, thanks to 
the closure of the injured vessel, and starts the second 
phase, facilitating platelet adhesion, by a change in 
the electric charge and exposure of the collagen fibers 
in the injured vascular wall (2), aided by a number of 
substances and structures that exist in the vascular 
endothelium (PGI2, ADP-asa, thrombomodulin, tissue 
Activators Plasminogen and von Willebrand factor, 
fibronectin, collagen fibers and proteoglycans, etc).
B) Platelet Activation. Platelets are cell fragments, 
without nucleic acids inside, of the megakaryocytes (3). 
Inside are two types of granules: a) α granules, round 
and ovoid. Containing hydrolytic enzymes, fibrinogen, 
platelet factor 4, clotting factors, trombostenina and 
other compounds b) dense granules containing serotonin, 
ADP, ATP, calcium, potassium, thromboxane A2 and 
substances involved in hemostasis. Platelet membrane is 
formed by a phospholipid-protein trilaminar membrane, 
whose inner part filaments communicate with the 
surface. On the surface of the membrane, appear many 
glycoproteins that are critical for platelet adhesion and 
aggregation.
In the platelet plug formation are two stages: Firstly 
apposition and platelet adhesion and secondly platelet 
aggregation and secretion (4-6).
II) Secondary Hemostasis
It’s called plasma phase, covering the phenomena of 
coagulation and fibrinolysis. Recently, it has been 
proposed a new model in clotting, which describes 
three phases (initiation phase, amplification phase and 
propagation phase). In this new model are provided 
novel concepts as “The Tisular complex factor-F VII” 
that participates in the activation of factor IX, what 
means that the intrinsic and extrinsic ways are linked 
almost from the beginning of the process and also, the 
full process is not made continuously but is done in three 
consecutive phases, actively participating in the last two, 
platelets and thrombin (7). Also of great importance 
is the recognition of the involvement of the cellular 
elements (typically not included in this phase), in which 
membranes and cellular structures numerous enzymatic 
processes and activation factors are produced equally. 
They intervene secreting substances and activating 
factors and their presence is crucial for the formation of 
complexes of factors with catalytic / accelerator ability 
of the  biochemical phenomenas that occur during the 
processes of coagulation activation. Last but not least, we 
must remember that in the plasma phase of hemostasis 
there are also included anticoagulation systems, which 
the body uses to maintain the vascular system without 
narrowing or blockages, which is mediated by protein 
S, protein C and thrombomodulin at the injury site.
III) Diagnostic tests for the evaluation of the 
hemostasis.
- Platelet count: The normal levels are between 150,000 
and 400,000 cell / mm3
- Morphology and platelet size control.
- Bleeding time: Ivy’s test measures the time in minutes 
and is usually less than 9.
- Platelet aggregation (8,9) is made by an aggregometer, 
that allows us to assess the state of platelet function .
- Prothrombin time (PT): Gives information about 
factors II, V, VII, IX and X and it is between 11-14 s.
- The international normalized ratio (INR): It’s a 
standardized method and is calculated by dividing the 
patient’s prothrombin time by the normal or control 
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prothrombin time, and all that, elevated to the ISI value 
(International Sensitivity Index). Their normal values 
are between 0.8 -1.2.
- Activated partial thromboplastin time (APTT): 
Measures the functionality of the intrinsic and common 
pathway of the coagulation cascade. Normal values 
vary from 25 to 40 s.
- Thrombin Time (TT): Time that plasma takes to 
coagulate by adding thrombin. Useful in qualitative 
and quantitative disorders of fibrinogen, presence 
of inhibitors of fibrinogen-fibrin conversion and 
polymerization inhibitors increase. Their normal values 
are 10 to 15 s.
- Quantification of coagulation factors and activity 
levels: On one hand, measures the quantity present and 
secondly the rate of activity of such factors.
II Hemostasis Patology
1) Primary Hemostasis Alterations: We are going to 
briefly describe then, the changes in the blood vessels 
(angiopathy) and platelets.
A) Changes in blood vessels: Vascular disorders are 
a heterogeneous group of diseases or conditions that 
are characterized by easy breakage, with consequent 
bleeding of small vessels (arterioles and capillaries) 
(10), Vascular purples enrolled usually minor bleeding 
in the skin, and in them, the coagulation tests and 
platelet count are usually normal. Vascular diathesis 
are classified  by hereditary / congenital disorders and 
acquired as shown in table 1, being bolded those one 
that have more interest for the dentist. In processes 
with altered subendothelial and perivascular tissue 
either congenitally or not, subcutaneous hemorrhages 
occur with minimal trauma, and wound healing will be 
hindered.
B) Platelet Disorders: inherited platelet disorders are 
a cause of haemorrhagic syndromes, although rare, 
ranging from minimal to severe bleeding (11). The 
clinic is similar in all platelet disorders, studying with a 
purpuric syndrome of cutaneous-mucosal multiple and 
spontaneous bleeding. We can distinguish two different 
types of alterations.
1) Thrombocytopenias: It’s when platelets are below 
150.000/mm3. The chances of bleeding when faced a 
trauma increase when the numbers are between 50.000 and 
100.000 / mm3 and if the figure is less than 20.000 / mm3, 
there’s risk of spontaneous bleeding. Table 2 describes 
the various possibilities differentiating between changes 
in production, increased destruction, alterations in the 
distribution and idiopathic or hereditary illnesses, also 
called hereditary thrombocytopenia (thrombocytopenia 
relatives). In them, there is not a sufficient number of 
platelets to ensure hemostasis (12). They usually have 
mild or moderate thrombocytopenia with bleeding little 
history consistent with platelet counts. Some family 
thrombocytopenia may also affect platelet morphology 
and / or function. Of all the above, the most interesting 
for dentists are marked in bold in table 2.
2) Thrombocytopathies: Functional disorders of platelets 
(also shown in table 2) are generally classified into primary 
or hereditary disorders and secondary or acquired. 
Primary abnormalities of platelet function are rare. By 
contrast, the acquired disorders are very common and are 
associated with common diseases in clinical practice and 
treatments administered to patients. Some authors (11), 
think that  primary alterations may be due to defects and 
/ or malfunctions in: the platelet surface glycoproteins, 
intraplatelets granules; cytoskeletal structural proteins 
of thrombocytes, catalytic / host / activating activity of 
the processes of plasmatic phase  in the hemostasis or in 
the transmission systems of messages / signals from the 
surface to the platelet cytoplasm. Those clinical entities 
that have more interest for the dentist are marked in bold 
in table 2 too.
2) Alterations in the plasmatic phase (coagulopathies) 
Plasmatic alterations that cause alterations in the 
secondary hemostasis process are generically called 
coagulopathies. Clinically are manifested with severe 
bruising, but it may also be manifested with bleed 
hemorrhages in the cutaneous-mucosal level. Alterations 
may appear both coagulation and fibrinolysis, and 
according to their origin; they are typically classified as 
congenital / hereditary and acquired (Table 3).
A) Pathology of Bleeding:
1) Congenital disorders: are perhaps the best-known 
1. Hereditary or Congenital Defects: 
    a) Vascular Malformations: 
     - Cavernous hemangioma (Kassabach-Merritt syndrome) 
     - Hereditary haemorrhagic telangiectasia (Rendu-Osler) 
     - Body Angiokeratoma diffuse (Fabry disease) 
     - Ataxia-Telangiectasia     
 b) Connective tissue disorders: 
- S. Ehlers-Danlos - S. Marfan 
- Pseudoxanthoma elasticum 
- Imperfect osteogenesis  
  2. Acquired Defects 
- Vascular immune purple (leukocytoclastic vasculitis): 
     * Schölein-Henoch disease 
     * Pharmacological: penicillin, sulfa, quinine, aspirin, etc.. 
     * Infectious: diphtheria, scarlet fever, f. typhoid, f. rheumatic, 
meningococcus and pneumococcus 
  - Vascular nonimmunologic purple: 
     * Thrombocytopenic thrombotic purple 
  - Alterations of subendothelial and perivascular connective tissue: 
     * Purple by avitaminosis C deficiency (scurvy) 
     * Cachectic purple 
     * Senile purple 
     * Purple by corticosteroid 
     * Amyloidosis 
Table 1. Clinical entities that can provoke alterations in vascular 
primary hemostasis.
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works at the level of the general population and are 
among others:
a) Haemophilia: There are two different clinical entities. 
One is haemophilia A, which lacks the factor VIII 
and constitutes 80-85% of cases. It linked recessive 
inheritance to chromosome X, although up to 30% of 
cases are spontaneous mutations. Depending on the 
degree of activity of the factor is classified (1) into: mild 
(6-30% factor activity), moderate (1-5% activity), and 
severe (<1% activity, ie <1 U / dl) with spontaneous 
bleeding. The normal rates of the factor range between 
50 and 100 IU per deciliter (1). The other is haemophilia 
THROMBOCYTOPENIAS
1. Abnormalities in platelet production: 
     A) Primary Medullary failure: aplastic medullary, primary amegakaryocytic Purple, Fanconi anemia, 
cancer therapy, infectious processes (s / t viriasis) Deficiency / nutritional disorders (vitamin B12 
deficiency and folic acid); Immune / farmacology origin, Etc. 
B) Bone Marrow Infiltration: Metastasis of solid tumors, hematologic neoplasms (leukemias, myelomas, 
lymphomas), Myelofibrosis… 
2. Increased Platelet Destruction: 
A. Not immune origin: 
a) Alteration in the platelet distribution: splenic sequestration, portal hypertension, splenomegaly. 
b) Secondary to therapeutic procedures: Heart valves prosthetic, extracorporeal circulation, 
hemodialysis. 
c) Vasculitis 
d) Microangiopathic destruction: CID;-Hemolytic Uremic Syndrome (HUS), Thrombocytopenic 
thrombotic purple (TTP). 
e) Giants hemangiomas: Kasabach-Merritt S. (It is a mixed process, so it also appears in the 
angiopathies) 
B.     Immune origin: Immune thrombocytopenias 
a) Due autoantibodies against platelet antigens: Idiopathic thrombocytopenic purple (ITP) (E. 
Welhorf) Post-transfusion purple, neonatal Isoimmunization 
b) Due antibodies against drugs: Heparin, Penicillin, quinine, thiazides, Interferon. 
c) Lymphoproliferative Diseases: Chronic Lymphoblastic Leukemia, Lymphoma 
d) Collagenosis: LED; Evans syndrom; Rheumatoid Arthritis 
e) Infection: Viruses, Bacteria, Sepsis 
3. Platelet distribution alterations (splenomegaly) 
a) Portal hypertension 
b) Major Thalassemia 
c) Gaucher Disease       
4.  Hereditary or family thrombocytopenias: 
A) Autosomal dominant thrombocytopenia  
B) Amegakaryocytic thrombocytopenia 
C) Alport Syndrome 
D) May-Hegglin Anomaly 
E) Mixed Forms: 
a. Thrombopenia with aplasia of the radius 
b. Wiskott-Aldrich Syndrome 
c. Chediak-Higashi syndrome
THROMBOCYTOPATHIES:
     1.   Primary platelet dysfunction: 
A) Changes in platelet adhesion: Bernard-Soulier syndrome 
B) Defects in platelet aggregation: Glanzmann Thrombasthenia 
C) Defects in storage, platelet secretion and / or transmission of the platelet activating signals: - gray platelet 
syndrome 
- Dense granules deficit 
- Defects in the primary receptors 
D) Changes in release mechanisms.    
2.  Secondary platelet dysfunction: 
- Uremia and Liver phatologies 
- Alcohol 
- Paraproteinemias 
- Degradation products of fibrin 
- Autoimmune Diseases 
- Myeloproliferative and myelodysplastic syndromes 
- Cardiac Surgery 
- Acquired von Willebrand Disease 
- Secondary to the use of drugs and natural products 
Table 2. Clinical entities that can result alterations in platelet primary hemostasis. 
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B, which lacks the F IX and constitutes 16% of cases. 
Its transmission is sex-linked recessive. Clinically 
indistinguishable from form A and its severity is also 
marked by the degree of activity.
b) Von willebrand disease: Also called Angiohemofilia 
and is due to congenital deficiency VWF variable 
that can be quantitative or qualitative. It is the most 
common inherited coagulopathy (13,14), affecting 
between 1-4% of the world population. The factor 
is a multimeric and multifunctional molecule that 
facilitates platelet adhesion after the loss of integrity 
of the endothelium of the vessels, while the phenomena 
involved in platelet aggregation and accompanies the 
factor VIII, transporting it through the bloodstream and 
protecting of plasma proteases (13). Diagnosis requires 
the presence of a history of bleeding, reduction in the 
number or functional impairment of von Willebrand 
factor and demonstration of its inheritance pattern. It’s 
divided into three main types (1) shown in table 3. VWF 
deficiency seems an impaired in the primary hemostasis 
and haemophilia A (especially the kind 3). The number 
of platelets is normal. Determination of bleeding time 
has little value in mild cases and is poorly reproducible. 
APTT may be normal or altered in types 1, 2a and 2b, 
whereas 2n and 3 are greatly altered. Definitive diagnosis 
gives VWF quantification by immunological methods. 
Appears muco-cutaneous bleeding and sometimes, 
delayed bleeding (in days) after extractions (10), rare 
joint bleeds (except type 3).
c)  Defects of others coagulation factors:
Its frequency is low, except the Factor XI, ranging from 
1/500.00 for F VII and 1/2.000.000 for prothrombin 
(FII) (1). All have autosomal heredity and, unless F XI 
deficiency, heterozygotes usually have no significant 
clinical manifestations (1).
d) Hypercoagulable Pictures: Also known as 
thrombophilia and can be defined as clinical entities with 
a tendency to hypercoagulability and thrombosis (15), 
they can be inherited or acquired. Despite the evidence 
demonstrated in numerous studies in cases of children 
who suffer strokes, this increased incidence of disorders 
/ thrombogenic factors of hereditary origin, they by 
themselves cannot fully explain their appearance, because 
only represent a minor / moderate risk factor (16). All of 
these entities are listed in table 4.
2) Alterations acquired
A) Current antibody inhibitor of factors: These are 
disorders that appear after repeated transfusions of 
factors to patients who lack them. Antibodies are 
produced by the body against exogenous factors, but 
may cross-react with proteins of coagulation. They are 
classified into specific and nonspecific:
B) Deficit of vitamin k: Vitamin K is needed for the 
processes of synthesis of factors II, VII, IX, and X 
as well as proteins S and C. Its deficiency causes an 
increased PT and APTT.
C) Liver diseases: The great importance of the liver 
in the level of the metabolic processes makes its 
dysfunction could interfere with the synthesis of 
vitamin K dependent factors, but there is also decreased 
factor V and fibrinogen. In addition, there may be 
thrombocytopenia, platelet dysfunction and primary 
hyperfibrinolysis. The combination of all this can give 
rise to different bleeding.
I)  PATHOLOGY OF COAGULATION:
A) CONGENITAL DISORDERS:
1) Haemophilia: 
a) Haemophilia a (F VIII) 
b) Haemophilia b (F IX)
2) Von Willebrand disease: (Angiohemofilia) 
a) Type 1 
b) Type 2: 
* 2a 
* 2b 
* 2m 
* 2n 
c) Type 3 
3) Defects in others coagulation factors: 
a) Alterations of fibrinogen (F I) 
b) Alterations of prothrombin (F II): 
c) Factor V Deficiency 
d) Factor VII Deficiency 
e) X Factor Deficit 
f) Factor XI Deficiency 
g) Factor XIII Deficiency 
h) Combined deficit of F V and F VIII 
i) Deficiency of depending factors of vitamin K 
 
 4) Hypercoagulability charts: 
a) Antithrombin III deficiency: 
* Quantitative 
* Qualitative (more frequent) 
b) Protein C deficiency: 
* homozygous 
* heterozygous 
c) Protein S Deficiency 
d) Factor V-Lieden: 
e) Contact factors deficiency. 
 
B) ACQUIRED ALTERATIONS 
 1)  Circulating antibodies factor inhibitors. 
  a) Specific antibodies (factors transfusion) 
  b) Nonspecific antibodies (AC antiphospholipid) 
 2) Deficiency of vitamin K 
3) Liver phaties 
4) Kidney Diseases 
5) Neoplasms 
6) Disseminated Intravascular Coagulation (DIC) 
7) Hypercoagulable charts 
 
II)  FIBRINOLYSIS PATHOLOGY:
1) ?2 antiplasmin deficiency 
2) Deficiency of the inhibitor-1 of the plasminogen activator  
Table 3. Clinical Entities that may lead to alterations in the plasma 
phase.
Med Oral Patol Oral Cir Bucal. 2014 May 1;19 (3):e280-8.                                                                                    Hemostasis disorders with repercussions in the odontostomatological treatments
e285
D) Kidney diseases: In nephrotic syndrome, thrombotic 
processes are described in the renal vein, but also in 
other vessels, associated with a decrease in antithrombin 
III, protein S and Factor XIII, on phenomena associated 
with platelet aggregation. By contrast, in terminal renal 
failure, there is a tendency to bleeding diathesis.
E) Neoplasias: The medical table may be due to 
oncotherapy administered to combat the processes, and/
or due to the clinical entity in itself.  They are mostly, 
haemorrhagic disorders.
F) Disseminated intravascular coagulation (DIC): In this 
condition, appears diffuse activation of all phenomena of 
hemostasis, with consumption of all the factors involved 
in the process as described above and consequently, the 
appearance of bleeding disorders that, if kept in time, 
can cause multi organic fails, and even patient’s death. It 
can be triggered by multiple factors (germs; neoplasms 
poisons; tissues damages;) acting self perpetuating the 
illness, so that treatment, in addition to etiologic should 
be supportive and substitution of products consumed.
1) Clinical History: It should incorporate medical history and patient treatments, a 
complete oral examination and all others tests necessary to perform to the patient. 
2) Interconsultations with the specialist or different specialists that treats the patient and 
that can provide information and guidelines for programming the patient for his dental 
treatment. 
3) Rating of: 
a) The place where the treatment takes place: Dental clinic or hospital 
environment
b) Number of appointments: single or multiple sessions. 
c) Treatment form: Ambulatory, by sedation or general anesthesia 
4) Oral-dental Treatment: Depending on the needs and characteristics of the patient: 
 a) Common procedures: 
  * Anesthesia (if applicable) 
* Aspiration 
* Rubber Dam (if applicable) 
b) Specific Treatments: 
  * Conservative: ... 
* Endodontics: ... 
* Periodontics: ... 
* Surgery: ... 
* Odonto-pedriatic: ... 
* Orthodontics: ... 
* Prosthetics: ... 
* ... 
5) Local hemostasis: 
 a) Gauzes: Alone or soaked with antifibrinolytic 
b) Cold 
c) Hemostatic plugs 
d) Sutures: Absorbable (Vicryl and similars) or not (silk, ...) 
e) Electric scalpel 
f) Platelet plug 
g) Microfibrillar collagen 
h) Fibrin sealants 
i) Cyanoacrylate adhesive. 
j) Compression trays 
6) Rescue treatment (2nd row): sometimes it’s given before the odonto-stomatology 
procedure
 a) Systemic antifibrinolytics: Tranexamic acid and EACA 
b) Desmopressin 
c) Fresh frozen plasma 
d) Platelet Transfusion 
e) Clotting Factors 
f) Recombinant Factor VIIa 
g) Hematopoietic stem cell transplantation 
h) Gene Therapy (in the near future) 
7) Post-treatment instructions 
8) Maintenance actions 
9) Prevention Program: Both secondary prevention, as primary or tertiary 
(individualized according to the patient's needs) 
Table 4. Systematic dental treatment planning. (19-27,30-35).
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G) Hypercoagulable illnesses: Inside acquired processes 
that can lead to hypercoagulability tables we could find 
the presence of antiphospholipid antibodies, anticardi-
olipin and / or anti-β2-glycoprotein I. It may also occur 
when increased rates of clotting factors, in hyperhomo-
cysteinemia, prolonged immobilization, aging, surgery, 
trauma, cancer, obesity, malnutrition, pregnancy, use of 
oral contraceptives and hormone replacement therapy 
(15,17).
B) Fibrinolysis pathology:
1) Deficit α2 antiplasmin: Autosomal recessive trans-
mission. Hemorrhages appear because hyperfibrinolytic 
and homozygous forms are similar to haemophilia. The 
treatment is done with plasma and antifibrinolytics are 
used preventively.
2) Deficit inhibitor-1 plasminogen activator: haemor-
rhagic manifestations appear for lack of control of fi-
brinolysis and not braking the activity of plasminogen 
activation factor.
III Therapeutic attitude of the dentist when 
facing these patients
When trying to control the bleeding, as well as local 
hemostasis actions, which we will see later, we can use 
various products such as:
1) Tranexamic Acid: Acts as antifibrinolytic and is more 
powerful than the epsilon amino caproic acid (EACA), 
whereby is rarely used oral level. It can be used as a 
systemic treatment with a dose of 20 mg / kg body 
weight or by local rinses, being a good adjuvant in the 
control of bleeding (18).
2) Desmopressin: It’s a synthetic analogue of the 
vasopressin hormone, but lacking vasopressor properties. 
Its administration increases plasma concentrations of 
F vW and F VIII. The response to the desmopressin 
is dose-dependent, reaching a maximum effect at 90-
120 minutes, and can be administered by intravenous 
infusion, subcutaneous injection or intranasal spray. 
Frequent repetition and close in time to administration 
brings a phenomenon of tachyphylaxis or acute tolerance. 
Because of this, some authors use it in a single dose, with 
good results (19).
3) Fresh frozen plasma: Although with prothrombotic 
supplements we must be very careful, for the risk of 
vascular obstruction (20), in FV-deficient patients, the 
infusion of 450 ml of fresh plasma raises the level of 
the factor 1% to 11% and passed 24 h, it’s maintained 
a level of 6%. Also the values  of TP and the TPPA are 
modified, passing from 20% to 50% passed 24 h (20).
4) Platelet Transfusions: indicated when the disorder 
is severe (less than 30,000 platelets) and when other 
therapeutic measures have not been effective. There is a 
risk of transmission of infectious diseases and reactions, 
recommending the platelet transfusion compatible with 
HLA (21).
5) Recombinant factor VIIa: Its own way of production is 
not immunogenic in patients with deficiency of factors, 
or not induce immune response when administered to 
patients previously sensitized by previous transfusions 
(patients with inhibitors), having a low thrombogenicity 
(22).
It’s suitable, in addition to F-deficient patients VII, 
in haemophiliacs and von Willebrand disease with 
inhibitors, being in most cases sufficient for a single dose 
application of the product (23). There are also articles 
describing their ability to control bleeding in patients with 
platelet disorders and other bleeding diathesis (24,25). 
The European Union approved its use in Glanzmann’s 
thrombasthenia refractory to platelet transfusions in 
patients with antibodies to GPIIb / IIIa (21).
The systematic assistance for oro-dental treatments 
for patients with this type of hemostatic disorders is 
common in many places, although in some tables some 
protocols or specific products are used.
It’s defined prolonged bleeding after tooth extraction, 
when it lasts more than three hours after surgery (26). 
In a patient with disorders of hemostasis, even a routine 
dental treatment such as a tooth extraction, can cause 
life-threatening situations (27). So, while in congenital 
disorders associated with platelet dysfunction, the 
therapies more often used are platelet transfusions 
in severe cases and desmopressin and antifibrinolytic 
drugs in mild cases, it is sometimes necessary to use 
the factors and alternative therapies, both in the preview 
preparation of the patient as in the rescue therapies after 
heavy and / or prolonged bleeding. In these patients, 
sometimes, it may consider hematopoietic stem cell 
transplantation as therapeutic tool and perhaps gene 
therapy will be the future for them (11,28). Also in certain 
acquired illnesses (as in the acquired von Willebrand 
disease) treatment may be as in the hereditary ones 
(29). In these type of patients, when planning a oral-
dental treatment plan, it’s necessary to assess the risk 
of bleeding and the pathology suffered by the patient. 
If it’s necessary a replacement or prophylactic therapy, 
the hematologist will be the one, once informed by the 
dentist, who has to design the preparation protocol of 
patient’s hemostasis.
Based on what it’s said above, as a systematic care for 
these patients, it’s proposed:
1. Clinical history: Medical and dental very exhaustive, 
with exploration and further tests for doing the treatment 
plan.
2. Internal consultation to the specialist (hematologist 
/ internist): It must be told, in plain language, all the 
planned treatment and the bleeding complications that 
may arise (by the type of treatment, oral health status 
and prior health degree, if the location of the procedure 
will be unique or it’s going to be done in several areas 
and the degree of contiguity between them). Based on 
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the information that we provide him, the hematologist 
will perform the treatment planning pre, intra and post 
operative required by the patient.
3. Considering the style of treatment (ambulatory, 
outpatient sedation or under general anesthesia), where 
doing it and if there is possibility to do it all in one 
session:  In case of require general anesthesia or factors 
infusion, platelets or any type of blood derivatives, 
will be held in a hospital environment. Sometimes, it 
can be performed on an ambulatory way, but always 
in intimate coordination with the hematology service. 
Doing everything in one session has the advantage 
of saving some cost of the complete treatment versus 
doing it in different sessions, but against this, there’s 
a several potential risk of haemorrhagic from different 
focus, and make a mutual decision in agreement with 
the hematologist. In case of performing under general 
anesthesia, intubation track is also subject to dispute, 
some authors prefers nasotracheal technique (18) 
and others oral one  (27), although both have the risk 
of submucosal hemorrhages in areas not accessible 
to visual inspection of the dentist, with danger of 
tracheobronchial aspiration.
4. Performing dental treatment: Except in rare 
circumstances, the first therapeutic risk actions will 
be the implementation of anesthesia to the patient. 
If it’s suggested, prevent nerve block anesthesia 
techniques, (in particular the inferior alveolar) if 
feasible, by the possible appearance of bruising in the 
areas of infiltration. Intraligamentous, intrapulpal, 
interpapillary or inflitratives anesthesia techniques 
are recommended in areas close to the periosteum and 
using anesthesia with vasoconstrictor, which will help 
to control bleeding. Once treatment begins, we must 
take precautions to make it the less traumatic treatments 
as possible, therefore:
a) In odontopediatric treatments:
- Not overused the instrumental in pulpotomy and 
pulpectomies
- Do not invade gums (supragingival pediatric dental 
crown)
- Cleaning carefully if there’s granulation tissue under 
the root for a better control of bleeding
b) In relation to aspiration:
- Support the nozzle on rollers or gauze and never 
directly on mucous
- Using spit ejector suction instead of surgical suction 
for being less traumatic.
c) According to the use of the rubber dam, there’s some 
authors that recommend it (27) because:
- Produces gingival retraction and field isolation
- Increases the operative visibility 
- Reduces the possibility of injuring lips and mucous 
membranes.
Since staples can be very traumatic, it’s recommendable 
to maintain the rubber dam with rubber cord pieces 
introduced between interdental space, if possible, and 
do not use wood shims for this technique.
d) In orthodontic treatments, bands, brackets and fixed 
maintainers, always cemented in a supragingival way.
e) Remember that early restorations prevent subsequent 
extractions, preferring pulpal protections than 
endodontics ones, and being careful with these last 
ones to do not overuse the instrumental in the apex. 
Extractions are the last option.
f) In the case of doing  extractions, though there are 
articles that don’t find advantages to suture wounds, 
facing not doing it (30), there’s some authors (27) that 
recommend doing them with  atraumatic needles, 
absorbable sutures and giving the least possible number 
of stitches.
5. Application of topical hemostasis ways and local 
measures: There are many possibilities and it’s often the 
combination of more than one way:
a) Autologous platelet plug associated with systemic 
tranexamic acid (31)
b) Desmopressin associated with topical tranexamic 
acid (mouthwashes) (32)
c) Surgicell® and wound closure (25)
d) Pressure with gauze soaked in tranexamic acid 
besides hemostatic plugs, associated with fibrin sealants, 
compression splints and antifibrinolytic rinses (33)
e) Surgicell or cellulose plugs or fibrin sponge or 
microfibrillar collagen or fibrin or cyanoacrylate 
adhesive, what means, material to fill the socket and 
antifibrinolytic rinses (27)
f) Splints: Using vacuum splints made  this controversial 
because some authors recommend them (34) while 
others criticize them (35) because they retain debris and 
detritus, which can lead to septic processes in the area.
6. Rescue treatment or 2nd row treatment: When all the 
actions seen above fail, we must appeal to other type 
of treatment. Normally, it’s usually done with blood 
derivates or recombinant factor, but always bearing in 
mind the circumstances of each patient (presence of 
inhibitors, etc.).
7. Scheduled instruction until post-treatment revision: 
Until the patient revision, including:
a) Diet: Cold liquid is recommended for 1-2 days after 
surgery and then soft diet until the removal of sutures 
and / or revision
b) Analgesia: Evite NSAIDs and administer paracetamol 
15 mg / kg every 6 h (18,27) Codeine can also be given, 
alone or in combination.
c) Desmopressin: If needed, a dose of 2 mg / kg at 12 
and 24 h. post treatment (18)
d) Antibiotics: To prevent over infection of the area, 
which could cause late bleeding (27)
8. Preventive and maintenance programs of oral 
hygiene:  The hygiene of patients with haemophilia 
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and von Willebrand disease is worse than the hygiene 
of other patients, attributed to fear of bleeding from 
tooth brushing (13). This can be extrapolated to patients 
with other types of disorders of hemostasis. However, 
the periodontal status of patients with von Willebrand 
disease who come regularly to dental examination 
is within the considered acceptable parameters (13). 
Preventive programs in this type of patient, should 
consider (27,33):
a) Vaccination against hepatitis B
b) Don’t take NSAIDs
c) Maintaining proper oral hygiene
d) Correction of iron deficiency
e) If the patient can rinse, use chemical control of plaque
f) Diagnosis and prenatal counseling in families with a 
background history.
9) Other circumstances: In patients with haemophilia, it 
has been observed that the emotional and psychological 
problems contribute to the onset of spontaneous bleeding 
(36). Similarly, some authors (1) reported that prolonged 
oral bleeding and for an extended period of time causes 
that hemosiderin and other degradation products of 
hemoglobin deposits on tooth structures, giving the 
tooth a dark discoloration.
References
1. Adeyemo TA, Adeyemo WL, Adediran A, Akinbami AJ, Akanmu 
AS. Orofacial manifestations of hematological disorders: anemia and 
hemostatic disorders. Indian J Dent Res. 2011;22:454-61. 
2. Murphy WG, Davies MJ, Eduardo A. The haemostatic response to 
surgery and trauma. Br J Anaesth. 1993;70:205-13.
3. Kaushansky K. Historical review: megakaryopoiesis and throm-
bopoiesis. Blood. 2008;111:981-6.
4. Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin 
Tromb Hemost. 2005;31:381-92.
5. Gibbins JM. Platelet adhesion signaling and the regulation of 
thrombus formation.  J Cell Sci. 2004;117:415-25.
6. Savage B, Cattaneo M, Ruggeri ZM. Mechanisms of platelets ag-
gregation. Curr Opin Hematol. 2001;8:270-6.
7. Pérez-Gómez F, Bover R. The new coagulation cascade and its 
possible influence on the delicate balance between thrombosis and 
hemorrhage. Rev Esp Cardiol. 2007;60:1217-9.
8. Seegmiller A, Sarode R. Laboratory Evaluation of platelet func-
tion. Hematolog Oncol Clin N Am. 2007;21:731-42.
9. Dyszkiewicz-Korpanty AM, Frenkel EP, Sarode R. Approach to 
assessment of platelet function: comparison between optical-based 
platelet-rich plasma and impedence-based whole blood platelet ag-
gregation methods. Clin Appl Thromb Hemost. 2005;11:25-35.
10. Eleftheriou D, Dillon MJ, Brogan PA. Advances in childhood 
vasculitis. Curr Opin Rheumatol. 2009;21:411-8.
11. Valera MC, Kemoun P, Cousty S, Die P, Payrastre B. Inherited 
platelet disorders and oral health. J Oral Pathol Med. 2013;42:115-
24.
12. Nurden AT, Freson K, Seligsohn U. Inherited platelet disorders. 
Haemophilia. 2012;18 Suppl 4:154-60. 
13. Benito Urdaneta M, Benito Urdaneta M, Ferrara Mendez V, 
Bernardoni Socorro C, Arteaga Vizcaíno M. Evaluating periodon-
tal conditions in patients with von Willebrand’s disease in Hospital 
Universitario de Maracaibo (University Hospital, Maracaibo)-Vene-
zuela. Med Oral Patol Oral Cir Bucal. 2008;13:e303-6.
14. Kadir RA, Sharief LA, Lee CA. Inherited bleeding disorder in 
older women. Maturitas. 2012;72:35-41.
15. Favaloro EJ, McDonald D, Lippi G. Laboratory investigation of 
thrombophilia: the good, the bad and the ugly. Semin Thromb He-
most. 2009;35:695-710.
16. Zadro R, Herak DC. Inherited prothrombotic risk factors in chil-
dren with first ischemic stroke. Biochem Med (Zagreb). 2012;22:298-
310.
17. Anderson JA, Weitz JI. Hypercoagulable states. Crit Care Clin. 
2011;27:933-52.
18. Bornert F, Clauss F, Gros CI, Faradji A, Schmittbuhl M, Manière 
MC, et al. Hemostatic management in pediatric patients with type 
I von Willebrand disease undergoing oral surgery: case report and 
literature review. J Oral Maxillofac Surg. 2011;69:2086-91.
19. Sánchez-Luceros A, Meschengieser SS, Woods AI, Chuit R, 
Turdó K, Blanco A, et al. Biological and clinical response to desmo-
pressin (DDAVP) in a retrospective cohort study of children with low 
von Willebrand factor levels and bleeding history. Thromb Haemost. 
2010;104:984-9.
20. Kitamura A, Yamashita H, Okumura T, Asahina I. Extraction of 
four wisdom teeth in a patient with congenital factor V deficiency 
haemophilia. Oral Surg Oral Med Oral Pathol Oral Radiol, Endod. 
2011;112:E1-3.
21. Geddis AF. Inherited thrombocytopenias an approach to diagno-
sis and management. Int Jnl Lab Hem. 2013;35:14-25.
22. Croom KF, McCormack PL. Recombinant factor VIIa (eptacog 
alfa): a review of its use in congenital hemophilia with inhibitors, ac-
quired hemophilia, and other  congenital bleeding disorders. BioD-
rugs. 2008;22:121-36.
23. Boadas A, Fernandez-Palazzi F, De Bosch NB, Cede-o M, Ruiz-
Sáez A. Elective surgery in patients with congénital coagulopathies 
and inhibitors: experience of the national Haemophilia Centre of 
Venezuela. Haemophilia. 2011;17:422-7.
24. Weeterings C, Lisman T, de Groot PG. Tissue factor-indepen-
dence effects of recombinant factor VIIa on hemostasis. Semin He-
matol. 2008;45:S12-5.
25. Hers I, Mumford A. Understanding the therapeutic action of re-
combinant factor VIIa in platelet disorders. Platelets. 2008;19:571-81.
26. Plugg I, Mauser-Bunschoten EP, Bröker-Vriends AHJT, Ploos 
van Amstel HK, van der Booms JG, van Diemen-Homan JEM, et al . 
Bleeding in carriers of haemophilia. Blood. 2006;108:52-6.
27. Rayen R, Hariharan VS, Elavazhagan N, Kamalendran N, Vara-
darajan R. Dental management of haemophiliac child under general 
anesthesia. J Indian Soc Pedod Prev Dent. 2011;29:74-9.
28. Nurden P, Nurden AT. Congenital disorders associated with 
platelet dysfunctions. Thromb Haemost. 2008;99:253-63.
29. Lison S, Dietrich W, Spannagl M. Review article: unexpected 
bleeding in the operating room: the role of acquired von Willebrand 
disease. Anesth Analg. 2012;114:73-81.
30. Jover-Cerveró A, Poveda-Roda R, Bagan JV, Jiménez-Soriano Y. 
Dental treatment of patients with coagulation factors alterations: an 
update. Med Oral Patol Oral Cir Bucal. 2007;12:e380-7.
31. Nurden P, Youlouz-Marfak I, Siberchicot F, Kostrzewa E, Andia 
I, Anitua E, et al. Use of autologous platelet-rich clots for prevention 
of local injury bleeding in patients with severe inherited mucocuta-
neous bleeding disorders. Haemophilia. 2011;17:620-4.
32. Nickles K, Wohlfeil M, Alesci S, Miesbach W, Eickholz P. Com-
prehensive treatment of periodontitis in patients with von Willebrand 
disease. J Periodontol. 2010;81:1432-40.
33. Seligsohn U. Treatment of inherited platelet disorders. Haemo-
philia. 2012;18 Suppl 4:161-5.
34. Israels S, Schwetz N, Boyar R, McNicol A. Bleedings disorders: 
Characterization, dental considerations and managements. J Can 
Dent Assoc. 2006;72:827-30.
35. Kumar NJ, Kumar RA, Varadarajan R, Sharma N. Specialty den-
tistry for the haemophiliac: is there a protocol in place?. Indian J 
Dent Res. 2007;18:48-54.
36. Chiono O. Dental anesthesia for the hemophilic patient. Anesth 
Prog. 1968;15:295-8.
